Cookies

We use cookies to ensure that we give you the best experience on our website. If you click accept my preferences we'll assume that you are happy to receive all cookies on our website. Visit our Cookie Policy and our Privacy Policy for more information about managing your cookies.


Current preferences
This site is intended for healthcare professionals
  • Sign in
  • /
  • Join us
Shop /
  • News
  • Specialty
    • Cardiovascular
    • Clinical Practice
    • Diabetes
    • Endocrinology
    • Musculoskeletal
    • Neurology
    • Oncology
    • Osteoporosis
    • Psychiatry
  • Viewpoint
  • COVID-19
  • Health Technology
  • Write for GM
    • Call for papers: common diseases
    • Author guidelines
  • MyCPD
  • White Papers
  • Digital Issues
  • Shop
  • Sign-in
  • Join us
  • News
  • Specialty
    • Cardiovascular
    • Clinical Practice
    • Diabetes
    • Endocrinology
    • Musculoskeletal
    • Neurology
    • Oncology
    • Osteoporosis
    • Psychiatry
  • Viewpoint
  • COVID-19
  • Health Technology
  • Write for GM
    • Call for papers: common diseases
    • Author guidelines
  • MyCPD
  • White Papers
  • Digital Issues

Sign In

Have you forgotten your password?

Don't have a https://www.gmjournal.co.uk account? create an account now

Confirm

Ok Cancel

Drinking coffee may reduce your chances of developing Alzheimer's disease

News, 06 November 2018
black-coffee.jpg

A new study suggests that drinking coffee may protect patients against developing both Alzheimer's and Parkinson's disease.

The study was conducted by the Krembil Brain Institute, part of the Krembil Research Institute and three different types of coffee - light roast, dark roast, and decaffeinated dark roast- were investigated.

Dr Donald Weaver, Co-director of the Krembil Brain Institute, said: "Coffee consumption does seem to have some correlation to a decreased risk of developing Alzheimer's disease and Parkinson's disease. But we wanted to investigate why that is - which compounds are involved and how they may impact age-related cognitive decline."

The research team identified a group of compounds known as phenylindanes, which emerge as a result of the roasting process for coffee beans. Phenylindanes are unique in that they are the only compound investigated in the study that prevent - or rather, inhibit - both beta amyloid and tau, two protein fragments common in Alzheimer's and Parkinson's, from clumping. 

As roasting leads to higher quantities of phenylindanes, dark roasted coffee appears to be more protective than light roasted coffee.

Dr Ross Mancini, a research fellow in medicinal chemistry, said: "It's the first time anybody's investigated how phenylindanes interact with the proteins that are responsible for Alzheimer's and Parkinson's. The next step would be to investigate how beneficial these compounds are, and whether they have the ability to enter the bloodstream, or cross the blood-brain barrier."

The fact that it's a natural compound vs. synthetic is also a major advantage, says Dr Weaver. "What this study does is take the epidemiological evidence and try to refine it and to demonstrate that there are indeed components within coffee that are beneficial to warding off cognitive decline. It's interesting but are we suggesting that coffee is a cure? Absolutely not."

 

email this article
Tags:
  • #cognitive decline
...

Comments

Write a Comment

Comment Submitted

...
  • News

  • Drinking during three critical stages cause a decline in brain health, say researchers
  • Cost of stroke care will soar in coming years without investment in prevention
  • Covid-19: 1 in 5 ischaemic stroke patients are from the Asian community
  • New study launched to 'retrain' the eyes following stroke
Contact Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
Tel: +44 (0)1273 434 943
Email: info@pavpub.com
© Pavilion Publishing and Media Ltd 2021
  • About GM
  • Cookie Consent
  • Information Security Statement
  • Privacy policy
  • Returns and cancellations
  • Terms and conditions
© Pavilion Publishing and Media Ltd 2021
back to top